Try our beta test site
20 studies found for:    (lymphoma [CONDITION] OR CLL [CONDITION]) AND "CMC-544" [TREATMENT]
Show Display Options
Rank Status Study
1 Completed Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma
Condition: Lymphoma
Intervention: Drug: Inotuzumab Ozogamicin (CMC-544)
2 Completed Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Condition: Lymphoma, B-Cell
Interventions: Drug: inotuzumab ozogamicin (CMC-544);   Drug: rituximab
3 Completed Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma
Condition: Lymphoma, B-Cell
Intervention: Drug: Inotuzumab ozogamicin [CMC-544]
4 Completed Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma
Condition: B-cell Lymphoma Refractory
Interventions: Drug: Inotuzumab Ozogamicin;   Drug: Temsirolimus
5 Completed Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma
Condition: Lymphoma, B-Cell
Interventions: Drug: inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone;   Drug: inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone
6 Completed Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab
Condition: Lymphoma, B-Cell
Interventions: Drug: Inotuzumab Ozogamicin (CMC-544);   Drug: Rituximab (Rituxan)
7 Completed Study Evaluating Safety and Tolerability of Inotuzumab Ozogamicin (CMC-544) in Japanese Patients With B-cell Non-Hodgkin's Lymphoma (NHL)
Condition: Lymphoma, B-Cell
Intervention: Drug: Inotuzumab Ozogamicin (CMC-544)
8 Completed Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)
Condition: B-Cell Lymphoma
Interventions: Drug: inotuzumab ozogamicin;   Drug: Rituximab
9 Completed Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse
Condition: Diffuse Large B-Cell Lymphoma
Intervention: Drug: Rituximab, CMC544, Gemcitabine and Oxaliplatine
10 Terminated A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: Inotuzumab ozogamicin;   Drug: Rituximab;   Drug: rituximab + gemcitabine;   Drug: rituximab +bendamustine
11 Terminated Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)
Condition: Lymphoma, Follicular
Interventions: Drug: inotuzumab ozogamicin;   Drug: rituximab;   Drug: cyclophosphamide;   Drug: vincristine;   Drug: prednisone/prednisolone;   Drug: mitoxantrone;   Drug: fludarabine;   Drug: dexamethasone
12 Recruiting CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies
Conditions: Lymphoma;   Leukemia
Interventions: Drug: CMC-544;   Drug: Fludarabine;   Drug: Bendamustine;   Drug: Rituximab;   Procedure: Allogeneic Stem Cell Transplantation;   Drug: Thymoglobulin;   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: G-CSF
13 Recruiting Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy
Condition: Diffuse Large B Cell Lymphoma
Interventions: Drug: Cyclophosphamide;   Drug: Vincristine;   Drug: Prednisolone;   Drug: Rituximab;   Drug: Inotuzumab Ozogamicin;   Drug: Gemcitabine
14 Recruiting S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia
Conditions: Acute Leukemias of Ambiguous Lineage;   B-cell Adult Acute Lymphoblastic Leukemia;   Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma
Interventions: Drug: cyclophosphamide;   Drug: vincristine sulfate;   Drug: prednisone;   Biological: inotuzumab ozogamicin;   Other: laboratory biomarker analysis
15 Active, not recruiting CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)
Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: CMC-544 (Inotuzumab Ozogamycin);   Drug: Rituximab
16 Active, not recruiting Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia
Condition: Acute Lymphocytic Leukemia
Intervention: Drug: Inotuzumab Ozogamicin
17 Not yet recruiting Inotuzumab Ozogamicin in Treating Younger Patients With Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Conditions: Childhood B Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Refractory Childhood Acute Lymphoblastic Leukemia
Interventions: Biological: Inotuzumab Ozogamicin;   Other: Laboratory Biomarker Analysis
18 Recruiting Study of the Combination of Inotuzumab Ozogamycin (CMC-544) With Low-intensity Chemotherapy in Patients With Acute Lymphoblastic Leukemia (ALL)
Conditions: Leukemia;   Acute Lymphoblastic Leukemia
Interventions: Drug: Inotuzumab Ozogamycin;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: Pegfilgrastim;   Drug: Methotrexate;   Drug: Ara-C;   Drug: 6-Mercaptopurine;   Drug: Prednisone;   Drug: Citrovorum
19 Active, not recruiting A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia
Condition: Acute Lymphoblastic Leukemia
Interventions: Drug: inotuzumab ozogamicin;   Drug: FLAG (fludarabine, cytarabine and G-CSF);   Drug: HIDAC (high dose cytarabine);   Drug: cytarabine and mitoxantrone
20 Recruiting Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive Philadelphia-Chromosome (PC) Positive Acute Lymphoblastic Leukemia (ALL) and Chronic Myeloid Leukemia (CML)
Condition: Leukemia
Interventions: Drug: Bosutinib;   Drug: Inotuzumab Ozogamicin;   Behavioral: Phone Call

Study has passed its completion date and status has not been verified in more than two years.